In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging

Archives of General Psychiatry

Volumn 57, Issue 1, 2000, Pages 47-53

  Bartzokis, George ^a,b,e   Sultzer, David ^b   Cummings, Jeffrey ^c   Holt, Lori E ^b   Hance, Darwood B ^b   Henderson, Victor W ^d   Mintz, Jim ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMAGE ANALYSIS; IRON STORAGE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; WHITE MATTER;

EID: 0033981049     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.1.47     Document Type: Article

References (91)

1. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55:809-815.
2. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88:10540-10543.
3. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol. 1993;34:609-616.
4. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994;36:747-751.
5. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995;45:1594-1601.
6. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol. 1996;149:21-28.
7. Davis S, Helfaer MA, Traystman RJ, Hurn PD. Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. Stroke. 1997;28:198-205.
8. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature. 1996;382:120-121.
9. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997;17:2653-2657.
10. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G, Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91:5710-5714.
11. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2, 4-dinitrophenylhydrazine. J Histochem Cytochem. 1998;46:731-735.
12. Halliwell B, Gutteridge JM. Iron as biological pro-oxidant. ISI Atlas Sci Biochem. 1988;1:48-52.
13. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41-51.
14. Klintworth GK. Huntington's chorea: morphologic contributions of a century. In: Barbeau A, Paulson GW, Chase TN, eds. Advances in Neurology, Vol 1: Huntington's Chorea, 1872-1972. New York, NY: Raven Press; 1973:353-368.
15. Bartzokis G, Mintz J, Sultzer D, Marx P, Herzberg JS, Phelan CK, Marder SR. In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol. 1994;15:1129-1138.
16. Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging. 1997;15:29-35.
17. Hallgren B, Sourander P. The non-haemin iron in the cerebral cortex in Alzheimer's disease. J Neurochem. 1960;5:307-310.
18. Ehmann WD, Markesbery WR, Alauddin M, Hossain TI, Brubaker EH. Brain trace elements in Alzheimer's disease. Neurotoxicology. 1986;7:195-206.
19. Dedman DJ, Treffry A, Candy JM, Taylor GA, Morris CM, Bloxham CA, Perry RH, Edwardson JA, Harrison PM. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's disease and chronic renal-dialysis patients. Biochem J. 1992;287:509-514.
20. Deibel MA, Ehmann WD, Markesbery WR, Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci. 1996;143:137-142.
21. Andorn AC, Britton RS, Bacon BR, Kalaria RN. Ascorbate-stimulated lipid peroxidation and non-heme iron concentrations in Alzheimer disease. Mol Chem Neuropathol. 1998;33:15-26.
22. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology. 1998; 19:339-345.
23. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res. 1992; 31:75-83.
24. Morris CM, Candy JM, Keith AB, Oakley AE, Taylor GA, Pullen RG, Bloxham CA, Gocht A, Edwardson JA. Brain iron homeostasis. J Inorg Biochem. 1992;47:257-265.
25. Floyd RA, Carney JM. The role of metal ions in oxidative processes and aging. Toxicol Ind Health. 1993;9:197-214.
26. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys. 1986;246: 501-514.
27. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994;343: 1199-1206.
28. Dai L. Winyard PG, Zhang Z, Blake DR, Morris CJ. Ascorbate promotes low density lipoprotein oxidation in the presence of ferritin. Biochim Biophys Acta. 1996; 1304:223-228.
29. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem. 1998;70:2492-2499.
30. Joshi JG. Ferritin: intracellular regulator of metal availability. In: Connor JR, ed. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997:131-143.
31. Dawson DA. Nitric oxide and oxidative damage in the CNS. In: Connor JR, ed. Metals and Oxidative Damage in neurological Disorders. New York, NY: Plenum Press; 1997:188-199.
32. Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun. 1995;216:702-707.
33. Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci. 1995;134(suppl):33-44.
34. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol. 1992;31:286-292.
35. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA. 1997; 94:9866-9868.
36. Makjanic J, McDonald B, Li-Hsian Chen CP. Watt F. Absence of aluminium in neurofibrillary tangles in Alzheimer's disease. Neurosci Lett. 1998;240:123-126.
37. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR, Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158:47-52.
38. Bouras C, Giannakopoulos P, Good PF, Hsu A, Hof PR, Perl DP. A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Eur Neurol. 1997;38:53-58.
39. Morris CM, Kerwin JM, Edwardson JA. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration. 1994;3:267-275.
40. Goodman L. Alzheimer's disease: a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 1953;118:97-130.
41. Grundke-Iqbal I, Fleming J,TungYC,Lassmann H, Iqbal K, Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia Acta Neuropathol (Berl). 1990;81:105-110.
42. Joshi JG, Fleming JT, Dhar M, Chauthaiwale V. A novel ferritin heavy chain messenger ribonucleic acid in the human brain. J Neurol Sci. 1995;134(suppl):52-56.
43. 2 values and iron levels. J Neurol Neurosurg Psychiatry. 1989;52:108-111.
44. 2 values in the human brain: comparison with quantitative assays of iron and ferritin. Radiology. 1989;173:521-526.
45. 2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol. 1993;14:275-281.
46. 2-weighted MR images. Radiology. 1989;173:311-312.
47. 2 signal. AJNR Am J Neuroradiol. 1994;15:1795-1796.
48. Malisch TW, Hedlund LW, Suddarth SA, Johnson GA. MR microscopy at 7.0 T: effects of brain iron. J Magn Reson imaging. 1991;1:301-305.
49. 2 relaxation time in the globus pallidus and putamen. Neuroradiology. 1993;35:119-124.
50. Bartzokis G, Sultzer D, Mintz J, Holt LE, Marx P, Phelan CK, Marder SR. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psychiatry. 1994;35:480-487.
51. Kamman RL, Go KG, Brouwer W, Berendsen HJ. Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature. Magn Reson Med. 1988;6:265-274.
52. Bartzokis G. Magnetic resonance imaging of brain iron. In: Connor JR, ed. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997:41-56.
53. Bartzokis G, Aravagiri M, Olderidorf WH, Mintz J, Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med. 1993;29:459-464.
54. Vymazal J, Brooks RA, Baumgarner C, Tran V, Katz D, Bulte JW, Bauminger R, Di Chiro G. The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med. 1996;35:56-61.
55. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn Reson Med. 1997;37:530-536.
56. 2-weighted MRI of normal gray matter and iron concentration. J Magn Reson Imaging. 1995;5:554-560.
57. 2 of ferritin solutions: effect of loading factor. Magn Reson Med. 1996;36:61-65.
58. Vymazal J, Brooks RA, Patronas N, Hajek M, Bulte JW, Di Chiro G. Magnetic resonance imaging of brain iron in health and disease. J Neurol Sci. 1995;134(suppl): 19-26.
59. 2-weighted with ageing images of normal subjects. Neuroradiology. 1998;40:76-80.
60. 2 relaxation at different field strengths. J Neurol Sci. 1995;134(suppl):10-18.
61. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol. 1987;149:365-379.
62. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 1995;65:710-716.
63. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ, Dick RD, Troyer MD, Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 1996; 738:265-274.
64. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem. 1995;65:717-724.
65. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia. 1993;4:61-65.
66. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
67. Folstein MF, Foistein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
68. Custer EM, Finch CA, Sobel RE, Zettner A. Population norms for serum ferritin. J Lab Clin Med. 1995;126:88-94.
69. Fleming J, Joshi JG. Ferritin: isolation of aluminum-ferritin complex from brain. Proc Natl Acad Sci USA. 1987;84:7866-7870.
70. Ebmeier KP, Besson JA, Crawford JR, Palin AN, Gemmell HG, Sharp PF, Cherryman GR, Smith FW. Nuclear magnetic resonance imaging and single photon emission tomography with radio-iodine labelled compounds in the diagnosis of dementia. Acta Psychiatr Scand. 1987;75:549-556.
71. Bondareff W, Raval J, Colletti PM, Hauser DL. Quantitative magnetic resonance imaging and the severity of dementia in Alzheimer's disease. Am J Psychiatry. 1988;145:853-856.
72. Besson JA, Crawford JR, Parker DM, Ebmeier KP, Best PV, Gemmell HG, Sharp PF, Smith FW. Multimodal imaging in Alzheimer's disease: the relationship between MRI, SPECT, cognitive and pathological changes. Br J Psychiatry. 1990; 157:216-220.
73. Hanyu H, Shindo H, Kakizaki D, Abe K, Iwamoto T, Takasaki M. Increased water diffusion in cerebral white matter in Alzheimer's disease. Gerontology. 1997;43: 343-351.
74. Hampel H, Teipel SJ, Alexander GE, Horwitz B, Teichberg D, Schapiro MB, Rapoport SI. Corpus cailosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis. Arch Neurol. 1998;55:193-198.
75. Olanow CW, Holgate RD, Murtaugh R, Martinez C. MR imaging in Parkinson's disease and aging. In: Calne DB, ed. Parkinsonism and Aging. New York, NY: Raven Press; 1989:155-164.
76. Youdim MB, Ben-Shachar D, Yehuda S, Riederer P. The role of iron in the basal ganglion. Adv Neurol. 1990;53:155-162.
77. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect. 1990;2:327-340.
78. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radio Biol Med. 1990;9:315-325.
79. 2. Biol Psychiatry. 1990;28:1027-1036.
80. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res. 1992;31:327-335.
81. Park BE, Netsky MG, Betsill WLJ. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology. 1975; 25:11.72-1178.
82. Sadeh M, Sandbank U. Neuroaxonal dystrophy and hemosiderin in the central nervous system. Ann Neurol. 1980;7:286-287.
83. Kim RC, Ramachandran T, Parisi JE, Collins GH. Pallidonigral pigmentation and spheroid formation with multiple striatal iacunar infarcts. Neurology. 1981;31: 774-777.
84. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem. 1990;55:342-345.
85. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging. 1999;17:213-222.
86. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56:569-574.
87. Campbell WG, Raskind MA, Gordon T, Shaw CM. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry. 1985;142:364-365.
88. Milton WJ, Atlas SW, Lexa FJ, Mozley PD, Gur RE. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. Radiology. 1991; 181:715-719.
89. Pujol J, Junque C, Vendrell P, Grau JM, Marti-Vilalta JL, Olive C, Gili J. Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol. 1992;49:711-717.
90. Andersen PB, Birgegard G, Nyman R, Hemmingsson A. Magnetic resonance imaging in idiopathic hemochromatosis. Eur J Haematol. 1991;47:174-178.
91. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337:1304-1308.